Newsfeeds - Spark Newswire

3 minute read

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More

May 16, 9:38 AM

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.

ATNX

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

May 6, 5:33 PM

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.

ACRX

6 minute read

83 Biggest Movers From Yesterday

By Lisa Levin

May 6, 5:22 AM

Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.

AENZ

4 minute read

57 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

May 5, 12:04 PM

Gainers

AIKI

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

May 4, 4:36 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

2 minute read

Earnings

Regenxbio’s Return On Capital Employed Overview

By Benzinga Insights

March 7, 10:48 AM

According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65 million in sales, a 1195.47% increase since Q3.

RGNX

2 minute read

Analyst Ratings

Expert Ratings For Regenxbio

By Benzinga Insights

March 2, 5:05 PM

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

RGNX

1 minute read

Earnings

Regenxbio: Q4 Earnings Insights

By Benzinga Insights

March 1, 5:47 PM

Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regenxbio beat estimated earnings by 41.61%, reporting an EPS of $6.67 versus an estimate of $4.71.

RGNX

3 minute read

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight

By Shanthi Rexaline

February 27, 10:26 AM

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.

ACAD